Skip to content
Clinical Trials – home

Clinical Research Hamburg GmbH

Verified siteinfo

Germany Spitalerstrasse 4, Hamburg-Altstadt, 20095 Hamburg, Germany

  • 4 trials recruiting
  • Asthma · COVID-19 · Influenza
  • Adults and children

About Specializations

Clinical Research Hamburg GmbH in Hamburg, Germany specialises in clinical trials of conditions such as Asthma, COVID-19, Influenza, Obesity, and other specialisations. This site conducts important research.

Main research areas of the site

Immune System Diseases and Allergy Research

At Clinical Research Hamburg GmbH, studies in immune system diseases focus on allergies and vaccine-related immune responses, with work spanning seasonal allergic rhinitis, rhinoconjunctivitis, and prevention of cytomegalovirus and respiratory syncytial virus infections. The main goal is to test new therapies and vaccines that may improve protection, symptom control, and immune response.

  • Evaluating new treatment options for birch pollen-induced allergy and related nasal and eye symptoms
  • Studying vaccine-induced immune responses for CMV and RSV prevention
  • Assessing safety and effectiveness of preventive approaches for viral respiratory infections

This area reflects a strong interest in both symptom relief and disease prevention, especially for people at higher risk of infection or persistent allergic disease.

Respiratory Tract Diseases and Viral Illnesses

Research in respiratory tract diseases includes asthma, influenza, COVID-19, and respiratory syncytial virus infection. The trials are designed to evaluate new medicines and vaccines that may reduce exacerbations, improve recovery, and lower the burden of respiratory illness in adults.

  • Testing treatments for high-risk COVID-19 outpatients
  • Studying better control of asthma symptoms and flare-ups
  • Evaluating vaccines for influenza and RSV prevention

The site’s respiratory portfolio combines treatment research with preventive vaccine studies, showing a broad effort to address both chronic and seasonal respiratory conditions.

Musculoskeletal Diseases and Pain Management

Trials in musculoskeletal diseases center on knee osteoarthritis and chronic non-specific low back pain. These studies aim to assess new options for pain relief, joint function, and possible cartilage support, helping to improve day-to-day mobility and quality of life.

  • Exploring treatments for knee osteoarthritis pain and joint health
  • Investigating therapy for chronic low back pain when standard options are not enough
  • Measuring whether new approaches can improve mobility and comfort

This research area is especially relevant for adults living with long-term pain conditions who may need alternatives to existing treatments.

Nutritional and Metabolic Diseases

The site also studies nutritional and metabolic diseases, including obesity, overweight, and gout with hyperuricemia. The purpose of these trials is to evaluate new therapies that may support weight management and better control of uric acid-related disease.

  • Testing treatment approaches for obesity and overweight
  • Assessing therapies for gout and elevated uric acid levels
  • Examining whether new medicines can improve long-term metabolic health

These studies address common chronic conditions where improved treatment options could have a meaningful impact on overall health and disease prevention.

Pathological Conditions, Signs and Symptoms and Smoking Cessation

Research in pathological conditions, signs and symptoms includes studies on vaping cessation in e-cigarette users and symptom-focused treatment for respiratory infections. The trials are intended to test whether new interventions can help people quit nicotine use and better manage short-term illness symptoms.

  • Supporting e-cigarette cessation and nicotine reduction
  • Tracking symptom improvement during viral respiratory illness
  • Evaluating whether treatment can help people recover more comfortably

At this Hamburg site, these studies add a practical public health dimension to the research portfolio by addressing behavior change and symptom relief.

Virus Diseases and Preventive Vaccination

A major part of the research at Clinical Research Hamburg GmbH involves virus diseases, especially COVID-19, influenza, respiratory syncytial virus, human metapneumovirus, and cytomegalovirus infection. The trials are focused on testing vaccines and antiviral strategies that may prevent infection or reduce the severity of disease.

  • Developing and evaluating vaccines for influenza, RSV, and CMV
  • Studying treatments aimed at reducing complications from COVID-19
  • Assessing prevention of viral lower respiratory tract disease in older adults

This infection-focused program shows a strong emphasis on prevention, immune protection, and better outcomes for adults at increased risk of viral illness.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Spitalerstrasse 4, Hamburg-Altstadt20095 HamburgGermany
Recruiting now
4 trials
Conditions studied
17
Partner status
Verified site

More sites in HamburgGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

18 clinical trials

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:GlaxoSmithKline Biologicals

Obesity+1

Not yet recruiting

A Phase III Study of Lenbelintide in Adults with Obesity or Overweight and Weight‑Related Comorbidity Without Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Hypercholesterolaemia

Not yet recruiting

Effect of laroprovstat/rosuvastatin combination versus laroprovstat, rosuvastatin, and placebo on LDL‑C in hypercholesterolemia patients not previously treated with lipid‑lowering therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Type 2 diabetes mellitus+2

Not yet recruiting

Effect of lenbelintide (AZD6234) on body weight in adults with type 2 diabetes and obesity or overweight

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Gout

Not recruiting

Study on the Effects of Tigulixostat and Allopurinol in Patients with Gout and High Uric Acid Levels

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol
  • Sponsor:LG Chem Ltd.

Asthma

Not recruiting

Comparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Chiesi Farmaceutici S.p.A.

Major depression

Not recruiting

Study of lavender oil (Silexan) in patients with mild to moderate major depressive disorder comparing its effectiveness to placebo

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lavender Oil
  • Sponsor:Dr. Willmar Schwabe GmbH & Co. KG

Influenza

Not recruiting

Study on the Safety and Immune Response of aQIVc HD Vaccine Compared to a Drug Combination for Adults 50 Years and Older at Risk of Flu Complications

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/(H3N2)-LIKE VIRUS ANTIGEN
  • Sponsor:Seqirus UK Limited
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.